Ambrilia Biopharma Inc. Sells Prostate Cancer Drug Candidate to Kotinos Pharmaceuticals Inc. for up to $15 Million

July 17, 2009 |

1 min read

Reuters -- Small Canadian biotech company Ambrilia Biopharma Inc said it agreed to sell its experimental prostate cancer drug, PCK3145, to Kotinos Pharmaceuticals Inc.

Mergers & acquisitions Australia

MORE ON THIS TOPIC

Insights

From Sound Bites to Signals: Editors Parse Executive and Investor Chatter at JPM

January 22, 2026

·

1 min read

·

Jennifer Smith-Parker

Facade of Novo Nordisk's office in Fremont, California

Cell therapy

After Cell Therapy Retreat, Novo Offloads Technologies in Deepened Aspect Pact

January 21, 2026

·

2 min read

·

Tristan Manalac

Reaching an agreement. Businessmen shake hands and make a deal. vector

Collaboration

GSK Joins Growing PD-1 SubQ Push With Alteogen Alliance Worth up to $285M+

January 21, 2026

·

1 min read

·

Tristan Manalac

Podcast

JPM26 Recap, Novo’s Oral Wegovy Soars as Lilly’s Orforglipron Is Delayed, IPOs Return

January 21, 2026

·

1 min read

·

Heather McKenzie